DUBLIN--(BUSINESS WIRE)--The "Global Hereditary Angioedema Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The Global Hereditary Angioedema Therapeutics Market to grow at a CAGR of 8.94% during the period 2018-2022.
The report covers the present scenario and the growth prospects of the hereditary angioedema therapeutics market. To calculate the market size, the report considers the revenue generated from the hereditary angioedema therapeutics. The report also includes a discussion of the key vendors operating in this market.
According to the report, one driver influencing this market is the increasing prevalence of hereditary angioedema. The rising cases of hereditary angioedema are increasing the possibility of transmission of the disease in the future generation. Therefore, it is expected that the distribution of the disease and the demand for the therapeutics will increase during the coming years, which in turn, results in the growth of the global hereditary angioedema therapeutics market.
Development of monoclonal antibody is one of the major trends in the market. The development of therapeutics for the treatment of disease requires various approvals and experimentation. Shire after conducting clinical trials for the treatment of hereditary angioedema, launched the first monoclonal antibody, Lanadelumab (SHP643)
Further, the report states that one challenge affecting this market is the high cost of treatment. Although the medications for HAE is covered under patient healthcare schemes in most countries, the indirect costs associated with the treatment makes the treatment quite expensive for the patients, leading to less patient adherence.
Key vendors
- BioCryst Pharmaceuticals
- Cipla
- CSL
- Pharming Group
- Shire
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: MARKET SIZING 2017-2022
PART 06: FIVE FORCES ANALYSIS
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY PRODUCT
- Segmentation by product
- Comparison by product
- C1 inhibitors
- Icatibant
- Ecallantide
- Others - Market size and forecast 2017-2022
- Market opportunity by product
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDS
- Innovative treatment strategies
- Improved route of administration products
- Development of monoclonal antibody
PART 14: VENDOR LANDSCAPE
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
For more information about this report visit https://www.researchandmarkets.com/research/bt2tqt/global_hereditary?w=4
